Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting

Cohen, Salomon Y.; Dubois, Lise; Tadayoni, Ramin; Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Delahaye-Mazza, Corinne; Guiberteau, B; Quentel, G

doi:10.1016/j.ajo.2009.04.001

Cited by 137 publications

(92 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within the current literature, there is a paucity of 'real-world' data with regard to outcomes of ranibizumab treatment for nAMD, and previous reports are often on small cohorts of patients despite originating from major institutions. [6][7][8][9][10][11][12][13][14][15][16] Few centres have emulated the mean VA gains of the ANCHOR and MARINA trials on unselected cohorts of patients. Table 3 compares the results in this study with that of the pivotal trials and pro re nata (PRN), and treat and extend reports demonstrating comparative mean VA at baseline and at 1 year.…”

Section: Discussionmentioning

confidence: 99%

“…[6][7][8][9][10][11][12][13][14][15][16] The aims of this paper are to establish VA outcomes and number of injections required each year for eyes with different baseline VA in a large cohort of treatment-naive patients in a real-world clinical setting. In addition, we wish to establish which measures of VA are the best measures of the quality of a service.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Ross

Donachie

Sallam

et al. 2012

Eye

View full text Add to dashboard Cite

Purpose The purpose of this study is to define which visual acuity (VA) measurements are the best indicators of highquality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD). Methods Analysis of prospectively collected data recorded within an electronic medical record system on treatment-naive, firsteligible eyes with nAMD, treated with ranibizumab using an as-needed treatment regimen with a minimum follow-up of 1 year. Data collection included the following: age, gender, laterality, type of nAMD, VA, central 1 mm OCT retinal thickness, number of intravitreal injections, and number of follow-up assessments. Results Data were available on the firsttreated eye from 406 patients with at least 1 year follow-up; of these, 198 had data at 2 years. The mean baseline VA of 54.4 Early Treatment Diabetic Retinopathy Study letters improved to 58.5 letters at 12 months and to 56.8 letters at 24 months. The mean VA changes from baseline to 1 year were þ 6.5, þ 7.5, þ 1.7, and À 1.5 letters, respectively, for baseline VA categories of 23-35, 36-55, 56-70, and 470 letters. Change in mean VA from the end of the loading phase to year 1 ranged from À 2.9 to þ 1.4 letters for the different baseline VA categories. The mean number of injections were similar across baseline VA categories ranging from 5.7 to 6.0 injections in year 1 and from 3.3 to 3.8 in year 2.Conclusions This large, real-world series demonstrates that mean change in VA is largely a function of selection criteria and baseline VA. The quality of a service is therefore better judged by actual VA outcomes and maintenance of vision after the loading phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Ross

Donachie

Sallam

et al. 2012

Eye

View full text Add to dashboard Cite

show abstract

“…Unfortunately, a strict monthly follow-up protocol with frequent OCT examinations is not possible in many clinical settings. It has been reported that outcomes following anti-VEGF therapy for exudative AMD are relatively unfavorable in the clinical setting [14,15]. The follow-up schedule and frequency of OCT examinations for the present study were not strictly controlled.…”

Section: Discussionmentioning

confidence: 99%

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Yoo

Kim

Han

et al. 2017

J Retin

View full text Add to dashboard Cite

Purpose:To investigate 2-year treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in eyes with polypoidal choroidal vasculopathy (PCV) with good baseline visual acuity. Methods: This retrospective, observational study included 21 eyes (10 eyes with a subfoveal polyp, 11 eyes with an extrafoveal polyp) of 21 subjects diagnosed with PCV. All eyes had a baseline best-corrected visual acuity (BCVA) of 20/25 or better and were administered an initial treatment of three intravitrial anti-VEGF injections at one-month intervals. Additional anti-VEGF treatments were administered as needed for recurring cases. BCVA and central foveal thickness (CFT) obtained 24 months after diagnosis were compared with baseline values. Results: Mean logarithm of the minimal angle of resolution (logMAR) BCVA was 0.07 ± 0.04 at baseline and 0.19 ± 0.29 approximately 24 months after initial diagnosis, a slight difference that was not statistically significant (p = 0.560). Of the 21 eyes included, 17 eyes (80.9%) had stable vision and 4 eyes (19.0%) had a ≥0.2 deterioration in logMAR BCVA. Twenty-four-month CFT (212.9 ± 76. 1 µm) was significantly lower than baseline CFT (324.6 ± 121.2 µm, p = 0.015). Conclusions: Two-year visual outcomes following anti-VEGF therapy in eyes with PCV and good initial visual acuity were generally favorable. However, logMAR BCVA deteriorated by ≥0.2 in 19.0% of treated eyes.

show abstract

“…The authors suggested that edema reduction could lead to visual acuity improvement, but the drug may also cause tissue hypoxia leading to deterioration of re tinal function (4) . Most studies on the use of ranibizumab for the treatment of neovascular AMD evaluated patients with relatively good vision (20/30-20/150) (5)(6)(7)(8) . The objective of the present study was to use mfERG to study patients with advanced neovascular AMD (visual acuity 20/100 or worse) in order to determine if retinal function improves after ranibizumab treatment.…”

Section: Introductionmentioning

confidence: 99%

Optical coherence tomography and multifocal electroretinography of patients with advanced neovascular age-related macular degeneration before, during, and after treatment with ranibizumab

Almeida¹,

Almeida

Sobrinho

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: To evaluate retinal morphology and function of patients with advanced neovascular age-related macular degeneration (AMD) before, during, and after treatment with ranibizumab. Methods: Twenty-one eyes diagnosed with advanced AMD were studied with optical coherence tomography (OCT) and multifocal electroretinography (mfERG). Three intravitreal injections of ranibizumab were administered at 1-month intervals. Evaluations were performed before the first injection (D0) and at 30 (D30), 60 (D60), and 90 days (D90) after the first injection and compared to an age-matched control group (n=21 eyes). Results: The thickness of macular retinal layers increased before treatment due to the presence of intraretinal fluid. A thick retinal pigment epithelium-choriocapillaris complex (RPE-CC) suggested the presence of choroidal neovascular membrane. Intraretinal edema decreased after treatment (P<0.01), but persisting RPE-CC thickness resulted in a subretinal scar. Three different annular retinal areas were studied with mfERG (from center to periphery: rings R1, R2, and R3). The amplitude of the first negative component (N1) decreased in R1, R2, and R3 at D30, D60, and D90 when compared with that in controls (P<0.05); the N1 implicit time was delayed in R3 at D30 (P<0.05). The amplitude of the first positive component (P1) was reduced in R1 and R2 at D30, D60, and D90 when compared with that in controls (P<0.01); the P1 implicit time was delayed in R1 at D0 and D60 (P<0.05), in R2 at D0, D30, and D90 (P<0.01), and in R3 at D30 and D60 (P<0.05). Conclusion: Ranibizumab reduces intraretinal edema, even in advanced cases. Central macular activity appeared to increase after the initiation of treatment, improving over time.Keywords: Macular degeneration/drug therapy; Antibodies; monoclonal, huma nized/therapeutic use; Tomography; optical coherence; Electroretinography; In travitreal injections RESUMO Objetivo: Avaliar a morfologia e função da retina em pacientes com doença macular relacionada à idade (DMRI), neovascular avançada, antes, durante e após o tratamento com ranibizumabe. Métodos: Vinte e um olhos com diagnóstico de DMRI avançada foram avaliados pela tomografia de coerência óptica (OCT) e eletrorretinografia multifocal (mfERG). Três injeções intravítreas de ranibizumabe foram administradas em intervalos de 1 mês. As avaliações foram realizadas antes da primeira injeção (D0) e aos 30 (D30), 60 (D60), e 90 dias (D90) após a primeira injeção e comparados com um grupo controle (n=21 olhos). Resultados: A espessura macular estava aumentada antes do tratamento devido à presença de fluido intrarretiniano, e o aumento da espessura do complexo EPR-CC foi compatível com a presença de membrana neovascular coroidal. O edema intrarretiniano diminuiu após o tratamento (P<0,01

show abstract

Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting

Cited by 137 publications

References 14 publications

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Optical coherence tomography and multifocal electroretinography of patients with advanced neovascular age-related macular degeneration before, during, and after treatment with ranibizumab

Contact Info

Product

Resources

About